Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy
Cardiovascular Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/cdr/5538781 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 27.06.2026. Verfasst von Yusof Kamisah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ukm.my. Hauptthemen laut MEDLINE: Prasugrel Hydrochloride, Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists, Acute Coronary Syndrome. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universiti Kebangsaan Malaysia.
Abstract (Originalsprache)
Managing acute coronary syndrome (ACS) and atherosclerotic cardiovascular disease remains clinically challenging, requiring a careful balance between ischemic protection and bleeding risk. Antiplatelet therapy is central to the management, with aspirin serving as the cornerstone; however, selection of the second antiplatelet agent in dual antiplatelet therapy (DAPT) remains complex. Clopidogrel, a purinergic receptor subtype Y, G protein–coupled, 12 (P2Y 12 ) inhibitor, is widely used but is limited by substantial interindividual variability in antiplatelet response, particularly in populations with a high prevalence of CYP2C19 loss‐of‐function polymorphisms. These limitations prompted the development of more potent P2Y 12 inhibitors, including prasugrel and ticagrelor, which provide faster and more consistent platelet inhibition. However, clinical experience—especially in Asian populations—has highlighted that a “one‐size‐fits‐all” dosing strategy may not be appropriate, as heightened bleeding risk can offset ischemic benefit. This review reexamines the contemporary role of prasugrel, focusing on evidence supporting dose optimization, careful patient selection, and population‐specific considerations. Current evidence suggests that prasugrel remains a valuable antiplatelet option when tailored to individual ischemic and bleeding risks, particularly in patients undergoing complex percutaneous coronary intervention and selected Asian populations requiring individualized antiplatelet strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ukm.my.
- Cardiovascular and Respiratory Research Group, Universiti Kebangsaan Malaysia, Bandar Baru Bangi, Selangor, Malaysia, ukm.my.
- Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ukm.my.
ORCID-Profile: Yusof Kamisah, Hamat Hamdi Che Hassan
Förderung
- Universiti Kebangsaan Malaysia
Zitieren
APA
Kamisah, Y., & Che Hassan, H. H. (2026). Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/5538781
Vancouver
Kamisah Y, Che Hassan HH. Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/5538781
BibTeX
@article{Kamisah2026,
author = {Kamisah, Yusof and Che Hassan, Hamat Hamdi},
title = {Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy},
journal = {Cardiovascular Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cdr/5538781}
}
EUVIMED